Angiogenesis inhibitors in cancer therapeutics

V. Krishnan, Usha Sadasivan

Abstract


In the era molecular pharmacology, development of angiogenesis inhibitors is certainly a master discovery .There are specific angiogenesis inhibitors are being used in cancer and various endogenous anti-angiogenesis molecules are discovered .This review is a coverage of basic anti-angiogenic molecule like bevacizumab and other newer targets, after explaining the basic physiology of new vessel formation which helps in better understanding of these drugs. 


Keywords


Angiogenesis, Angiogenesis inhibitors, Cancer

Full Text:

PDF

References


Thomas, Sticker, Vinay Kumar, et al. Robbins basic pathology .Tissue repair. 8th ed. Boston: Saunders an imprint of Elsevier; 2012:173.

Bruce A. Chabner, Jeffery Branes, Joel Neal, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2012: 1732-1750

Gresset Shah, et al. Intricacies of bevacizumab induced toxicity. Ann Pharmacother. 2009;43:490-501.

Edward, Sausvile, Dan L Lango, et al. Harrison principle of internal medicine. Principle of cancer management. 18th edition. New York, NY: McGraw-hill; 2012: 514-533.

V. Damiano, D. Melisi, C. Bianco et al. “Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.” Clinical Cancer Research. 2005;11(15):5639–44.

National cancer institute, drug information. 2013. Available at http://www.cancer.gov/cancertopics/druginfo/fda-axitinib. Accessed 17 Dec 2013.

National cancer institute, drug information. 2013. Available at http://www.cancer.gov/cancertopics/druginfo/fda-pazopanibhydrochloride. Accessed 17 Dec 2013.

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients with Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol. 2009;27(19):3126-32.

Aflibercept vs Placebo in Metastatic Colorectal Cancer After Failure of an Oxaliplatin-Based Regimen) trial. J Clin Oncol. 2012;30:3499-3506.

S. L. Goodman, G. Hölzemann, G. A. G. Sulyok, and H. Kessler. Nanomolar small molecule inhibitors for alpha(V) beta(6), alpha(V)beta(5), and alpha(V)beta(3) integrins. Journal of Medicinal Chemistry. 2002;45(5)1045–51.

O. Schnell, B. Krebs, E. Wagner et al. “Expression of integrin alpha(V)beta(3) in gliomas correlates with tumor grade and is not restricted to tumor vasculature.” Brain Pathology. 2008;18(3):378–86.

S. Filleur, O. V. Volpert, A. Degeorges et al. “In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.” Genes and Development. 2001;15(11):1373–82.

J. F. De Groot, M. Prados, T. Urquhart, et al. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. Journal of Clinical Oncology. 2009;27(15supplement):2047.

S. L. Goodman, G. Hölzemann, G. A. G. Sulyok, and H. Kessler. Nanomolar small molecule inhibitors for alpha(V) beta(6), alpha(V)beta(5), and alpha(V)beta(3) integrins. Journal of Medicinal Chemistry. 2002;45(5):1045–51.

O. Schnell, B. Krebs, E. Wagner, et al. Expression of integrin alpha(V)beta(3) in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathology. 2008;18(3):378–86.